Newsroom

In This Section

News Release

Mallinckrodt Announces Journal Publication of Economic Evidence for TERLIVAZ® (terlipressin) for Injection in Adults with Hepatorenal Syndrome (HRS)

Print Page | RSS Feeds | Email Alerts

Building On Our Heritage

More than 150 years of quality, integrity and service.

Learn More

Join Us

Invest in your own career with Mallinckrodt and let’s do something dynamic together..

Learn How